Coronado Biosciences, Falk, OvaMed In TSO Pact

Coronado Biosciences, Inc. has signed a collaboration agreement with Dr. Falk Pharma GmbH and OvaMed GmbH for the development of TSO (Trichuris suis ova or CNDO-201) for Crohn’s disease.

Falk has granted Coronado exclusive rights and licenses for certain preclinical data and clinical data from Falk’s clinical trials of TSO in Crohn’s disease, including an ongoing Phase II trial, for use in North America, South America and Japan. Coronado granted Falk exclusive rights and licenses to data from Coronado’s clinical trials of TSO in Crohn’s disease for use in Europe. Falk will receive a total of $6.6 million after receipt of certain preclinical and clinical data and a royalty of 1% of TSO sales.

Coronado licensed TSO, an orally administered, natural immunomodulator that regulates T-Cells and inflammatory cytokines, from OvaMed, the manufacturer of the product, in North America, South America and Japan. Falk licensed TSO from OvaMed for gastroenterology indications in Europe. Coronado and Falk will each be responsible for clinical testing for regulatory approval of TSO for Crohn’s disease in the U.S. and Europe, and will share certain preclinical development costs.